Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Opus Genetics (IRD – Research Report), retaining the price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on the successful outcomes of Opus Genetics’ Ryzumvi in its Phase 3 LYNX-2 trial, which met its primary endpoint. The trial demonstrated a significant improvement in visual acuity for patients with DLD post-refractive surgery, with a notable percentage of patients achieving a ≥15-letter gain compared to placebo. The safety profile of Ryzumvi remained consistent with previous studies, and no new safety concerns were identified, further supporting the therapy’s potential.
Additionally, the lack of available therapies for this indication and the statistically significant data from the LYNX-2 trial bolster confidence in the drug’s clinical and regulatory prospects. The anticipated timeline for further trials and potential approval, along with the possibility of label expansion to other indications, suggests a promising revenue stream for Opus Genetics. These factors, along with upcoming pipeline catalysts, reinforce the Buy rating for Opus Genetics’ stock.
In another report released on May 16, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.